Comportamiento de las crisis hipertensivas

Leonardo Reyes Corona, Manuel René Reytor Gutiérrez, Armando Corona Castellanos

Texto completo:

PDF PDF

Resumen

Se realizó un estudio descriptivo, prospectivo y de carácter longitudinal en el Hospital “Gelacio Calaña” del municipio de Niquero en el período comprendido entre enero a diciembre del 2006. El universo de estudio lo constituyeron todos los pacientes que acudieron al cuerpo de guardia de nuestro hospital con manifestaciones de crisis hipertensivas (200 pacientes), de ellos escogimos una muestra representativa de 128 pacientes de diferentes sexos, edades y razas. Nuestro estudio tuvo como objetivo fundamental determinar el comportamiento de las crisis hipertensivas en el período estudiado. Se estudiaron variables como edad, sexo, raza, causas más frecuentes, síntomas al ingreso y evolución de las crisis. Hubo predominio del sexo femenino, del grupo etáreo de 61 a 70 años y la raza negra. El síntoma al ingreso resultó ser el dolor precordial. Las causas que mas influyeron en la aparición de las crisis hipertensivas fueron las idiopáticas. Las encefalopatías hipertensivas fueron las crisis más frecuentes. La evolución fue favorable ya que la gran mayoría de las crisis fueron yuguladas.

Palabras clave

HIPERTENSIÓN /quimioterapia; AGENTES ANTIHIPERTENSIVOS /uso terapéutico, HIPERTENSIÓN/epidemiología; EVOLUCIÓN CLÍNICA

Referencias

Nawarskas JJ, Crawford MH. Avances recientes en el tratamiento de las crisis hipertensivas. Cardiol Clin Annu Drugs Ther. 2004; 2: 21-33.

Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The fifth Report. Arch Intern Med. 1999; 153: 154-83.

J.N. C.IV. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol. 1999; 35: 747-62.

Gales MA. Oral antihypertensives for hypertensives urgencies. Ann Pharmacother. 1999; 28: 352-8.

Zampaglione B, Pascale C, Marchisio M. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hipertensión. 2001; 27: 144-7.

Franklin et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1999; 157: 2413-46.

Hirschl MM. Guidelines for the drug treatment of hypertensive crises. Drugs. 2001; 50: 991-1000.

A bbran CVS. Immediate management of severe hypertension. Cardiol Clin. 2005; 13: 579-91.

Javier Leon PJ. et al. Nonemergent hypertension: new perspectives for emergency medicine physician. Emerg Med Clin North Am. 2004; 13: 1009-35.

Castañeda et al. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 2001; 92: 1326-31.

Duprez De TD. et al. Nifedipine associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Arch Intern Med 2005; 107:185-6.

Psaty BM, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 2001; 274: 620-5.

Pahor M, Guralnik JM, Corti M. Long-term survival and use antihypertensive medications in older persons. J Am Geriatr Soc. 2006; 43: 1191-7.

Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 2004; 92: 1068-73.

Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA. 2004; 275: 423-4.

Tedesco MA, Wachter RM. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. Arch Intern Med. 2005; 147: 556-7.

De Simone, Zangerle KF, Wolford R. Syncope and conduction disturbances following sublingual nifedipine for hypertension. Ann Emerg Med. 2001; 14: 1005-6.

Ghanem WISAM MA, Schwartz M, Naschitz JE, Yeshurun D. Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose. Arch Intern Med. 2005; 150: 686-7.

Shakim Eric, Houston MC. Pathophysiology, clinical aspects, and treatment hypertensive crises. Prog Cardiovasc Dis. 2005; 32: 99-148.

Grossman E, Messerli FH, Grodzicki T. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 2005; 276: 1328-31.

Kaplan NM. Hypertension. En: Year book of Cardiology. Harcourt Brace. 2006: 287-8.

Rehnman F, Mansoor GA, White WB. Inappropiate physician habits in prescribing oral nifedipine capsules in hospitalized patients. Am J Hypertens. 2001; 9: 1035-9.

Jick H, Derby LE, Gurewich V. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmatherapy. 2001; 16: 321-6.

Kaplan NM. Do calcium antagonist cause death, gastrointestinal bleeding, and cancer? Am J Cardiol. 2005; 78: 932-3.

Gradman AH, Arcuri KE, Goldberg AI. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 2005; 25: 1345-50.

Ruff D, Gazdick LP, Berman R. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens. 2001; 14: 263-70.

Townsend R, Haggert B, Liss C. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 2005; 17: 911-23.

Tikkanen I, Omvik P, Jensen HAE. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 2004; 13: 313-9.

Gray RJ, Bateman TM, Czer LSC. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol. 2004; 59: 887-91.

Muzzi DA, Black S, Losasso TJ. Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth Analg. 2001; 70: 68-71.

Miller DR, Martineau RJ, Wynands JE. Bolus administration of esmolol for controlling the haemodynamics response to tracheal intubation: the Canadian multicenter trial. Can J Anaesth. 2002; 38: 849-58.

Dyson A, Isaac PA, Pennant JH. Esmolol attenuates cardiovascular responses to extubation. Anesth Analg. 2004; 71: 675-8.

Grossman et al. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 2004; 28: 190-202.

Reilly CS, Wood M, Koshakji RP. Ultra-short acting beta-blockade: A comparison with conventional beta-blockade. Clin Pharmacol Ther. 2006; 38: 579-85.

Deegan R, Wood AJJ. b-receptor antagonism does not fully explain esmolol induced hypotension. Clin Pharmacol Ther. 2005; 56: 223-8.

Askenasi J, Maccosbe PE, Hoff J. Hemodynamic effects of esmolol, an ultrashort-acting betablocker. J Clin Pharmacol. 2004; 27: 567-73.

Esmolol Research Group. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of multicenter, baseline-controlled safety and efficacy study in 160 patients. Am Heart J. 2005; 112: 498-505.

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2020 MULTIMED

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.